Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology.
Ocular Therapeutix Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.91|
|52 Week High||US$6.73|
|52 Week Low||US$24.30|
|1 Month Change||-34.13%|
|3 Month Change||-38.69%|
|1 Year Change||-32.12%|
|3 Year Change||30.87%|
|5 Year Change||17.92%|
|Change since IPO||-47.45%|
Recent News & Updates
Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Ocular Therapeutix: Why I'm Buying The Dip
OCUL has dropped substantially since a December 2020 stock offering. It is a platform company with already approved products. In my view, the approved products justify the current beaten down valuation, leaving plenty of blue sky for the remaining pipeline.
Most Shareholders Will Probably Find That The CEO Compensation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Is Reasonable
Performance at Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) has been reasonably good and CEO Antony Mattessich has done a...
|OCUL||US Pharmaceuticals||US Market|
Return vs Industry: OCUL underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.
Return vs Market: OCUL underperformed the US Market which returned 30.3% over the past year.
Stable Share Price: OCUL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: OCUL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease.
Ocular Therapeutix Fundamentals Summary
|OCUL fundamental statistics|
Is OCUL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OCUL income statement (TTM)|
|Cost of Revenue||US$42.48m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.34|
|Net Profit Margin||-318.76%|
How did OCUL perform over the long term?See historical performance and comparison
Is Ocular Therapeutix undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OCUL ($6.91) is trading below our estimate of fair value ($113.74)
Significantly Below Fair Value: OCUL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OCUL is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: OCUL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OCUL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OCUL is overvalued based on its PB Ratio (6.6x) compared to the US Pharmaceuticals industry average (3x).
How is Ocular Therapeutix forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCUL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OCUL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OCUL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OCUL's revenue (42% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: OCUL's revenue (42% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OCUL's Return on Equity is forecast to be high in 3 years time
How has Ocular Therapeutix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OCUL is currently unprofitable.
Growing Profit Margin: OCUL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OCUL is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.
Accelerating Growth: Unable to compare OCUL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCUL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: OCUL has a negative Return on Equity (-128.25%), as it is currently unprofitable.
How is Ocular Therapeutix's financial position?
Financial Position Analysis
Short Term Liabilities: OCUL's short term assets ($216.5M) exceed its short term liabilities ($21.6M).
Long Term Liabilities: OCUL's short term assets ($216.5M) exceed its long term liabilities ($128.9M).
Debt to Equity History and Analysis
Debt Level: OCUL's debt to equity ratio (62.6%) is considered high.
Reducing Debt: OCUL's debt to equity ratio has increased from 22% to 62.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCUL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OCUL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Ocular Therapeutix current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OCUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OCUL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OCUL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OCUL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OCUL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Antony Mattessich (54 yo)
Mr. Antony Mattessich serves as Director of Aura Biosciences, Inc. since September 2021. He has been the Chief Executive Officer and President of Ocular Therapeutix, Inc. since July 26, 2017. Mr. Mattessic...
CEO Compensation Analysis
Compensation vs Market: Antony's total compensation ($USD2.16M) is about average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Antony's compensation has increased whilst the company is unprofitable.
Experienced Management: OCUL's management team is considered experienced (3.8 years average tenure).
Experienced Board: OCUL's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OCUL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.4%.
Ocular Therapeutix, Inc.'s employee growth, exchange listings and data sources
- Name: Ocular Therapeutix, Inc.
- Ticker: OCUL
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$529.188m
- Shares outstanding: 76.58m
- Website: https://www.ocutx.com
Number of Employees
- Ocular Therapeutix, Inc.
- 24 Crosby Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/24 22:20|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.